Earnings summaries and quarterly performance for Blueprint Medicines.
Executive leadership at Blueprint Medicines.
Kathryn Haviland
Detailed
President and Chief Executive Officer
CEO
Ariel Hurley
Detailed
Senior Vice President, Finance and Principal Accounting Officer
Becker Hewes
Detailed
Chief Medical Officer
Christina Rossi
Detailed
Chief Operating Officer
Debra Durso-Bumpus
Detailed
Chief People Officer
Fouad Namouni
Detailed
President, Research and Development
Michael Landsittel
Detailed
Chief Financial Officer
Percy Carter
Detailed
Chief Scientific Officer
Philina Lee
Detailed
Chief Commercial Officer
Tracey McCain
Detailed
Chief Legal and Compliance Officer
Board of directors at Blueprint Medicines.
Research analysts who have asked questions during Blueprint Medicines earnings calls.
Ami Fadia
Needham & Company, LLC
3 questions for BPMC
Also covers: ACAD, ALKS, AVDL +10 more
Laura Prendergast
Raymond James
2 questions for BPMC
Also covers: ALLO, RVMD
Reni Benjamin
Citizens JMP Securities
2 questions for BPMC
Also covers: ALLO, BCAB, BGNE +7 more
Sudan Loganathan
Stephens Inc.
2 questions for BPMC
Also covers: ADCT, ARVN, CPRX +6 more
Andrew Berens
Leerink Partners
1 question for BPMC
Also covers: AGIO, ARVN, BGNE +6 more
Brad Canino
Stifel Financial Corp.
1 question for BPMC
Also covers: KYTX, SMMT
Colleen Kusy
Robert W. Baird & Co.
1 question for BPMC
Also covers: APLS, CHRS, EYPT +5 more
David Lebowitz
Citigroup Inc.
1 question for BPMC
Also covers: ALNY, ARWR, ASND +11 more
Derek Archila
Wells Fargo
1 question for BPMC
Also covers: APLS, ARGX, ARVN +9 more
Marc Frahm
TD Cowen
1 question for BPMC
Also covers: ADAP, AGIO, CRDF +7 more
Michael Schmidt
Guggenheim Securities
1 question for BPMC
Also covers: ADAP, ADCT, ARVN +19 more
Michael Yee
Jefferies
1 question for BPMC
Also covers: ALLO, AMGN, BEAM +14 more
Paul Jeng
Guggenheim Partners
1 question for BPMC
Also covers: ADAP, IMCR, INCY +2 more
Peter Lawson
Barclays PLC
1 question for BPMC
Also covers: ADAP, ARVN, CTMX +15 more
Ren Benjamin
Citizen at JPM
1 question for BPMC
Also covers: INCY, SLS
Tommie Reerink
Goldman Sachs
1 question for BPMC
Also covers: ALNY, ATRA, BMRN +2 more
Recent press releases and 8-K filings for BPMC.
Blueprint Medicines Corporation Acquired by SANOFI Subsidiary for $9.1 Billion Plus CVRs
BPMC
M&A
Takeover Bid
Delisting/Listing Issues
- Blueprint Medicines Corporation (BPMC) completed its merger with Rothko Merger Sub, Inc., a wholly owned subsidiary of SANOFI's Aventis Inc., on July 17, 2025.
- The acquisition was structured as a tender offer, with shareholders receiving $129.00 per Share in cash plus one non-transferable contractual contingent value right (CVR) per Share.
- Each CVR represents the right to receive contingent payments of up to an aggregate amount of $6.00 per Share in cash upon the achievement of specified milestones.
- The aggregate cash consideration paid by the Purchaser for the shares in the offer and merger was approximately $9.1 billion.
- As a result of the merger, BPMC became a wholly owned subsidiary of Aventis, and its shares will be delisted from Nasdaq.
Jul 18, 2025, 12:00 AM
Blueprint Medicines presents long-term AYVAKIT data at 2025 EHA and EAACI congresses
BPMC
- Blueprint Medicines showcased a decade of collaboration and data presentations for AYVAKIT®/AYVAKYT® at the 2025 EHA and EAACI congresses, emphasizing its role as a durable standard of care in both indolent and advanced systemic mastocytosis.
- PIONEER three-year results demonstrated sustained symptom improvements through 144 weeks, with a 3 % discontinuation rate due to treatment-related adverse events and a median exposure of three years (some patients treated up to five years).
- PATHFINDER and EXPLORER multi-year analyses showed prolonged overall survival with AYVAKIT versus real-world midostaurin data across all risk categories, validated by the new MARS-R prognostic tool.
- PRISM survey data highlighted the substantial real-world burden of indolent systemic mastocytosis on patients’ physical, social and emotional well-being.
Jun 12, 2025, 10:01 PM
Blueprint Medicines Acquisition Announced by Sanofi
BPMC
M&A
- Sanofi announced it will acquire Blueprint Medicines to expand its portfolio in rare immunological diseases and boost its early-stage immunology pipeline.
- The acquisition includes Blueprint’s approved Ayvakit/Ayvakyt for systemic mastocytosis and advanced candidates like elenestinib and BLU‑808.
- The deal terms feature a cash offer of $129.00 per share (totaling approximately $9.1 billion) plus contingent value rights for potential milestone payments.
Jun 2, 2025, 12:00 AM
Blueprint Medicines Q1 2025 Earnings & Clinical Update
BPMC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Q1 2025 net product revenues reached $149.4M from AYVAKIT/AYVAKYT sales—including $129.4M in the U.S.—with 61% YoY growth .
- Raised full-year AYVAKIT net product revenue guidance to $700–$720M, supporting a longer-term target of $2B by 2030 .
- Robust growth in patient starts and prescriber expansion driven by targeted allergist initiatives and plans to expand into dermatology and gastroenterology .
- Clinical progress includes advancement in the HARBOR study of elenestinib and initiation of BLU-808 proof-of-concept studies for allergic rhinoconjunctivitis and chronic urticaria, with a sustained favorable safety profile over three years .
- Demonstrated a strong balance sheet with an approximate cash position of $900M, including a $78.7M boost from an equity investment sale .
May 1, 2025, 12:01 PM
Blueprint Medicines Showcases Mast Cell Therapy Data at AAAAI/WAO Joint Congress
BPMC
New Projects/Investments
- AYVAKIT demonstrated strong long-term efficacy and safety in ISM with three-year follow-up data from the PIONEER trial, showing durable symptom improvement and positive effects on bone health.
- BLU-808 displayed a wide therapeutic window and favorable tolerability in Phase 1 trials, supporting its potential as a first-in-class oral wild-type KIT inhibitor.
Feb 28, 2025, 1:00 PM
Blueprint Medicines Q4 & FY2024 Results with 2025 Guidance & Strategic Updates
BPMC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Q4 2024 & FY2024 Performance: Reported Q4 total revenue of $146.4M (with $144.1M in net product sales and a $50.0M net loss) and full-year revenue of $508.8M.
- AYVAKIT Growth: Achieved $479.0M in net product revenues in 2024 (including $144.1M in Q4) with 135% YoY growth, driven by strong performance in both US and ex‑US markets.
- 2025 Guidance: Expects global AYVAKIT revenues of $680–710M (approx. 45% YoY growth) with a long-term target of $2B by 2030, alongside an updated systemic mastocytosis franchise peak opportunity of $4B.
- Strategic & Clinical Updates: Highlighted the presentation of 14 abstracts at major conferences, promising Phase 1 healthy volunteer data for BLU-808, and increased investments in R&D, SG&A, commercial infrastructure, and field team expansion supported by a robust cash position of $864M and reduced operating cash burn.
Feb 13, 2025, 12:00 PM
Quarterly earnings call transcripts for Blueprint Medicines.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more